Brokerages Set Niagen Bioscience, Inc. (NASDAQ:NAGE) Target Price at $10.33

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have been assigned a consensus rating of “Buy” from the five ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $10.3333.

Several research firms have recently commented on NAGE. Freedom Capital raised shares of Niagen Bioscience to a “strong-buy” rating in a research report on Monday, July 6th. HC Wainwright reissued a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, July 1st. Roth Capital reissued a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, August 5th. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Friday, July 17th. Finally, Wall Street Zen lowered Niagen Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th.

Institutional Trading of Niagen Bioscience

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. purchased a new position in Niagen Bioscience during the third quarter worth about $37,522,000. SteelPeak Wealth LLC purchased a new stake in shares of Niagen Bioscience in the 1st quarter valued at approximately $14,875,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Niagen Bioscience by 47.1% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock worth $10,489,000 after acquiring an additional 761,685 shares during the last quarter. Tieton Capital Management LLC acquired a new position in shares of Niagen Bioscience in the 2nd quarter worth approximately $6,407,000. Finally, UBS Group AG lifted its holdings in shares of Niagen Bioscience by 18.0% in the 4th quarter. UBS Group AG now owns 1,411,742 shares of the company’s stock worth $8,979,000 after acquiring an additional 215,645 shares during the last quarter. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

Niagen Bioscience Trading Up 1.0%

Niagen Bioscience stock opened at $3.08 on Wednesday. Niagen Bioscience has a 12-month low of $2.87 and a 12-month high of $10.52. The stock has a market cap of $245.29 million, a P/E ratio of 17.11 and a beta of 2.09. The company has a 50-day moving average price of $3.36 and a 200 day moving average price of $4.26.

Niagen Bioscience (NASDAQ:NAGE) last posted its earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%. The company had revenue of $29.78 million for the quarter, compared to analyst estimates of $29.95 million. As a group, analysts forecast that Niagen Bioscience will post 0.13 EPS for the current year.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.